NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com/.
Company profile
Ticker
NRXS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
IRS number
455079684
NRXS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
8-K
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Departure of Directors or Certain Officers
11 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Feb 24
8-K
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
31 Jan 24
424B3
Prospectus supplement
19 Dec 23
8-K
Other Events
19 Dec 23
Latest ownership filings
3
Kristin A Ferge
15 Mar 24
4
Brian Hannasch
29 Feb 24
4
Brian Hannasch
14 Feb 24
SC 13G/A
Hannasch Brian
14 Feb 24
4
Brian Hannasch
23 Jan 24
SC 13G
Hannasch Brian
26 Dec 23
3
Brian Hannasch
13 Dec 23
3
Adrian Miranda
13 Sep 23
4/A
Change in insider ownership (amended)
11 Aug 23
4
Change in insider ownership
10 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 761.25 k | 761.25 k | 761.25 k | |||
Cash burn (monthly) | (no burn) | 1.01 mm | (no burn) | |||
Cash used (since last report) | n/a | 6.93 mm | n/a | |||
Cash remaining | n/a | -6.17 mm | n/a | |||
Runway (months of cash) | n/a | -6.1 | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Brian Hannasch | Common Stock | Grant | Dispose A | No | No | 0 | 75,000 | 0.00 | 757,901 |
28 Dec 23 | Brian Hannasch | Common Stock | Sell | Dispose S | No | No | 2.61 | 76 | 198.36 | 532,901 |
28 Dec 23 | Brian Hannasch | Common Stock | Acquire X | No | No | 0.005 | 40,000 | 200.00 | 532,977 | |
28 Dec 23 | Brian Hannasch | Warrant (right to purchase) Common Stock | Dispose X | No | No | 0.005 | 40,000 | 200.00 | 0 | |
11 Aug 23 | Masimo | Common Stock | Conversion | Acquire C | No | No | 0 | 531,548 | 0.00 | 531,548 |
11 Aug 23 | Masimo | Pre-Funded Warrant, Common Stock Common Stock | Conversion | Acquire C | No | No | 0.0005 | 289,779 | 144.89 | 289,779 |
11 Aug 23 | Masimo | Pre-Funded Warrant, Series A Preferred Stock Series A Preferred Stock | Conversion | Dispose C | No | No | 0.0001 | 144,890 | 14.49 | 0 |
11 Aug 23 | Masimo | Series A Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 265,774 | 0.00 | 0 |
Press releases
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9 Apr 24
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
1 Apr 24
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
27 Mar 24
NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
27 Feb 24